The PharmaMedia
June 17, 2022

Editor's note: This English translation was done by a third party. The original digital story can be accessed here.

News: The list of side effects of the popular hair loss drug will expand

The U.S. Food and Drug Administration previously approved revised guidelines for Propecia (finasteride) that mentioned the risks of persistent sexual dysfunction and depression, but not suicide.

The Post-Finasteride Syndrome Foundation, a patient advocacy organization, petitioned the FDA in 2017 to order the drugmaker, Merck & Co, to either stop selling the hair loss drug or to change its label. At the same time, the Post-Finasteride Syndrome Foundation referred to several scientific studies.

However, the American regulator refused to remove the popular hair loss drug Propecia and its generics from the market, but required the manufacturer to report the suicidal behavior of men taking the drug. The agency said the group's petition "does not provide reasonable evidence" for a causal relationship between finasteride use and sexual problems, depression, or suicide.

But taking into account patient reports, the FDA will still require that the list of side effects listed in the instructions for Propecia be expanded to include "suicidal thoughts and behavior."